ITGAX and melanoma: Indeed, in the hDC-SIGN:CD11c humanized mice, targeting OVA to hDC-SIGN on DCs elicited antigen-specific CD8+ T cell responses capable of eradicating OVA-expressing melanoma tumors (14).